Charles Schwab
ERNA icon

Charles Schwab’s Eterna Therapeutics ERNA Stock Holding History

Charles Schwab’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed -$130K – 3567
2022
Q1 		$130K Sell
8
-2
-20% -$37.9K ﹤0.01% 3375
2021
Q4 		$315K Hold
10
– – ﹤0.01% 3274
2021
Q3 		$701K Buy
10
+2
+25% +$173K ﹤0.01% 3023
2021
Q2 		$1.05M Buy
+8
New +$1.15M ﹤0.01% 2909

Other funds holding ERNA

CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's ERNA Position: Q2 2022 in Review

Charles Schwab sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 8 shares — an estimated $130K sold.

Charles Schwab first reported a position in ERNA in Q2 2021 and held it in 4 quarters. The position peaked at $1.05M in Q2 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

  • Charles Schwab reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 8 Eterna Therapeutics shares in Q2 2022, an estimated $130K.
  • Charles Schwab first reported a position in Eterna Therapeutics in Q2 2021 and held it in 4 quarters.
  • Charles Schwab's Eterna Therapeutics position peaked at $1.05M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.